High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood.
A new immunoglobulin (Ig) for intravenous use was given in high doses to 4 children with refractory idiopathic thrombocytopenic purpura (ITP) and 2 children with idiopathic aplastic anemia (IAA). Within 5-10 days after initiation of Ig therapy the platelets of the children with ITP rose to 300,000-650,000/mm3 and could be maintained at normal levels with one Ig infusion every 1-3 weeks. No reaction was observed in the 2 patients with IAA.
D000293:Adolescent; D000741:Anemia, Aplastic / Q000188:drug therapy; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D011379:Prognosis; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous